Role of pentoxifylline in non-alcoholic fatty liver disease in high-fat diet-induced obesity in mice

Table 5 Adipokine profile of lean (control) and obese (high-fat diet) mice treated with pentoxifylline

	Control		HFD
	NT	PTX	NT	PTX
TNF-α (pg/mL)	87.2 ± 2.8	75.5 ± 3.9	106.1 ± 17.6	51.1 ± 9.6c
IL-6 (pg/mL)	227.9 ± 23.3	178.5 ± 30.9	340.8 ± 51.3	166.6 ± 22.5c
PAI-1 (pg/mL)	600.2 ± 32.3	1508.6 ± 210.4c	2646.3 ± 755.1a	4434.5 ± 1400.1
MCP-1 (pg/mL)	287.8 ± 17.1	253.8 ± 13.3	721.5 ± 112.8a	563.8 ± 109.7
Leptin (ng/mL)	8.1 ± 0.7	23.1 ± 2.9c	26.6 ± 3.0a	20.5 ± 3.7
Adiponectin (ng/mL)	109.1 ± 0.5	102.8 ± 0.6	106.8 ± 1.7	102.8 ± 5.9

^aP < 0.05 vs control NT group;

^cP < 0.05 vs the matched NT group. HFD: High-fat diet; NT: Non-treated; PTX: Pentoxifylline; TNF-α: Tumor necrosis factor α; IL-6: Interleukin-6; MCP: Monocyte chemoattractant protein-1; PAI: Plasminogen activator inhibitor-1.